ARROWHEAD PHARMACEUTICALS, INC. Quarterly Deferred Tax Assets, Gross in USD from Q3 2013 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
Summary
Arrowhead Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Gross history and growth rate from Q3 2013 to Q3 2024.
  • Arrowhead Pharmaceuticals, Inc. Deferred Tax Assets, Gross for the quarter ending September 30, 2024 was $473M, a 55.4% increase year-over-year.
Deferred Tax Assets, Gross, Quarterly (USD)
Deferred Tax Assets, Gross, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $473M +$169M +55.4% Sep 30, 2024 10-K 2024-11-26
Q3 2023 $304M +$41.6M +15.8% Sep 30, 2023 10-K 2024-11-26
Q3 2022 $263M +$46.6M +21.6% Sep 30, 2022 10-K 2023-11-29
Q3 2021 $216M +$45.2M +26.4% Sep 30, 2021 10-K 2022-11-28
Q3 2020 $171M +$54.1M +46.3% Sep 30, 2020 10-K 2021-11-22
Q3 2019 $117M -$9.23M -7.31% Sep 30, 2019 10-K 2020-11-23
Q3 2018 $126M -$23.7M -15.8% Sep 30, 2018 10-K 2019-11-25
Q3 2017 $150M +$7.3M +5.12% Sep 30, 2017 10-K 2018-12-11
Q3 2016 $143M +$37.1M +35.2% Sep 30, 2016 10-K 2017-12-12
Q3 2015 $105M +$43.2M +69.5% Sep 30, 2015 10-K 2016-12-14
Q3 2014 $62.2M +$2.91M +4.9% Sep 30, 2014 10-K 2015-12-14
Q3 2013 $59.3M Sep 30, 2013 10-K 2014-11-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.